PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (AU1991080881) Immunoassay of elastin peptides in urine

Office : Australia
Application Number: 80881/91 Application Date: 10.05.1991
Publication Number: 1991080881 Publication Date: 04.02.1993
Publication Kind : A
Prior PCT appl.: Application Number:US1991003252 ; Publication Number: Click to see the data
IPC:
G01N 33/68
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
CPC:
G01N 33/6884
Applicants: Graduate Hospital Foundation Research Corporation
Inventors: Kucich, Umberto
Rosenbloom, Joel
Weinbaum, George
Priority Data: 522447 11.05.1990 US
Title: (EN) Immunoassay of elastin peptides in urine
Abstract:
(EN) This invention is a non-intrusive, quantitative urine test of improved sensitivity capable of identifying the presence of lung damage in asymptomatic patients. The invention is useful in monitoring the progression of lung diseases. The method comprises steps of preparing a synthetic peptide or providing elastin-derived peptides and using either the synthetic peptide or the elastin-derived peptides to generate antibodies. The antibodies are then incubated with increasing amounts of the synthetic or elastin-derived peptides in an indirect ELISA. An antibody and peptide mixture is applied to microtiter plates coated with the elastin-derived or synthetic peptide so that the antibodies and peptides combine to form a first complex. The microtiter plates containing the first complex are washed to remove excess unbound antibodies. A known amount of a conjugate of enzyme-antibody is then used and a standardization curve is prepared. An unknown sample of urine with elastin-derived peptides is analyzed in accordance with the above steps. Data are then corrected for creatinine excretion and compared to the standardization curve to determine whether the amount of elastin-derived peptides in the unknown urine sample to establish the existence of lung disease.
Also published as:
WO/1991/018290